Det finske biotekselskab Forendo Pharma, der har danske Novo Seeds som storinvestor, har netop fået de sidste data i hus fra selskabets nyligt afsluttet fase 1-forsøg med en lægemiddelkandidat til behandling af sygdommen endometriose, der rammer op mod hver 10. kvinde.
Og det er gode data, skal man tro Forendos bestyrelsesformand, danske Stephan Christgau, der også er seniorpartner i Novo Seeds.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for AMWatch has now started
With your free trial you get:
Full access to all locked articles on AMWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.
More from AMWatch
Focusing on Nordic fixed-income funds has doubled Alfred Berg's market shares in Norway. The company, which was previously a prominent player in Sweden, is hoping to carry this success over to the Swedish market, which it has been mostly absent from since selling the majority of its funds to Carneo two years ago.